secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001517022-25-000030
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia shareholders approve 18.9M share increase to 2023 Stock Incentive Plan
-----------------------------------------------------------------------------

- Shareholders approved amendment to 2023 Stock Incentive Plan to increase shares by 18,900,000 (102.75M for, 48.21M against).
- Directors John P. Butler and Myles Wolf re-elected as Class II directors with over 119.9M votes each.
- Advisory vote on executive compensation passed with 110.68M for, 39.01M against.
- Ratification of Ernst & Young as auditor for 2025 passed with 178.59M for, 8.90M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000030/0001517022-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000030/akba-20250610.htm
  HTML page:      https://secwatch.observer/filing/0001517022-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer